scholarly journals Letter to the Editor about the Beltrán‐Corbellini et al . publication: ‘Acute‐onset smell and taste disorders in the context of Covid‐19: a pilot multicenter PCR‐based case‐control study’ ( Eur J Neurol 2020. doi: 10.1111/ene.14273)

2020 ◽  
Vol 27 (9) ◽  
Author(s):  
J. R. Lechien ◽  
C. Hopkins ◽  
S. Saussez
2020 ◽  
Vol 27 (9) ◽  
pp. 1738-1741 ◽  
Author(s):  
Á. Beltrán‐Corbellini ◽  
J. L. Chico‐García ◽  
J. Martínez‐Poles ◽  
F. Rodríguez‐Jorge ◽  
E. Natera‐Villalba ◽  
...  

Author(s):  
Kamil Adamczyk ◽  
Michal Herman ◽  
Janusz Fraczek ◽  
Robert Piec ◽  
Barbara Szykula-Piec ◽  
...  

Blood ◽  
1993 ◽  
Vol 82 (9) ◽  
pp. 2714-2718 ◽  
Author(s):  
DW Kaufman ◽  
JP Kelly ◽  
CB Johannes ◽  
A Sandler ◽  
D Harmon ◽  
...  

Abstract The relation of acute thrombocytopenic purpura (TP) to the use of drugs was investigated in a case-control study conducted in eastern Massachusetts, Rhode Island, and the Philadelphia region; 62 cases over the age of 16 years with acute onset and with a rapid recovery were compared with 2,625 hospital controls. After control for confounding by multiple logistic regression, use of the following drugs in the week before the onset of symptoms was significantly associated: trimethoprim/sulfamethoxazole (relative risk [RR] estimate, 124), quinidine/quinine (101), dipyridamole (14), sulfonylureas (4.8), and salicylates (2.6). The overall annual incidence of acute TP was estimated to be 18 cases per million population. The excess risks for the associated drugs were estimated to be 38 cases per million users of trimethoprim/sulfamethoxazole per week, 26 per million for quinidine/quinine, 3.9 per million for dipyridamole, 1.2 per million for sulfonylureas, and 0.4 per million for salicylates. Associations with sulfonamides, quinidine/quinine, sulfonylureas, and salicylates have been previously reported, but the present study has provided the first quantitative measures of the risk. The association with dipyridamole was unexpected. In general, despite large RRs, the incidence rates attributable to the drugs at issue (excess risks) were low, suggesting that TP is not an important consideration in the use of the various drugs.


Author(s):  
Mohammad Raeisi ◽  
Kurosh Kalantar ◽  
Bahia Namavar Jahromi ◽  
Behrouz Gharesi-Fard

This is a Letter to the Editor and does not have an abstract.


BJPsych Open ◽  
2019 ◽  
Vol 5 (2) ◽  
Author(s):  
Eva Hesselmark ◽  
Susanne Bejerot

BackgroundPaediatric acute-onset neuropsychiatric syndrome (PANS), an umbrella term that includes PANDAS (paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) is suggested to be a psychiatric disorder of autoimmune aetiology. PANS is characterised by an acute onset of obsessive–compulsive disorder or restricted eating with multiple comorbid symptoms. The specificity of the PANS criteria is not fully understood.AimsTo describe a cohort of patients with PANS and to determine if PANS features relating to symptoms, onset and course are more common in PANS than in other psychiatric conditions.MethodA case–control study comparing patients with interview-confirmed PANS with patients with suspected PANS and patients with a psychiatric condition but with no suspicion of PANS. Validated and non-validated measures of symptoms, onset and episodic course were used.ResultsIllness in patients with interview-confirmed PANS featured an episodic course and multiple symptoms present at onset compared with the psychiatric controls. However, individuals with interview-confirmed PANS did not present a specific symptom profile.ConclusionsPANS may be a distinct clinical entity featuring an acute onset, an episodic course and multiple symptoms at onset.Declaration of interestNone.


Sign in / Sign up

Export Citation Format

Share Document